ATE542522T1 - Wässrige pharmazeutische formulierung - Google Patents

Wässrige pharmazeutische formulierung

Info

Publication number
ATE542522T1
ATE542522T1 AT08735958T AT08735958T ATE542522T1 AT E542522 T1 ATE542522 T1 AT E542522T1 AT 08735958 T AT08735958 T AT 08735958T AT 08735958 T AT08735958 T AT 08735958T AT E542522 T1 ATE542522 T1 AT E542522T1
Authority
AT
Austria
Prior art keywords
aqueous pharmaceutical
pharmaceutical formulation
benzopyran
povidone
ylmethyl
Prior art date
Application number
AT08735958T
Other languages
English (en)
Inventor
Dieter Gillessen
Juergen Jaeger
Original Assignee
Acino Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acino Pharma Ag filed Critical Acino Pharma Ag
Application granted granted Critical
Publication of ATE542522T1 publication Critical patent/ATE542522T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT08735958T 2008-04-08 2008-04-08 Wässrige pharmazeutische formulierung ATE542522T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2008/054232 WO2009124586A1 (en) 2008-04-08 2008-04-08 Aqueous pharmaceutical formulation

Publications (1)

Publication Number Publication Date
ATE542522T1 true ATE542522T1 (de) 2012-02-15

Family

ID=40239668

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08735958T ATE542522T1 (de) 2008-04-08 2008-04-08 Wässrige pharmazeutische formulierung

Country Status (12)

Country Link
EP (1) EP2280688B1 (de)
JP (1) JP2011516509A (de)
KR (1) KR20110008055A (de)
CN (1) CN102112108A (de)
AT (1) ATE542522T1 (de)
AU (1) AU2008354622A1 (de)
BR (1) BRPI0822580A2 (de)
CA (1) CA2721014A1 (de)
MX (1) MX2010011117A (de)
TW (1) TW200942240A (de)
WO (1) WO2009124586A1 (de)
ZA (1) ZA201007185B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2680832T (lt) 2011-03-04 2019-10-25 Gruenenthal Gmbh Tapentadolio vandeninė farmacinė kompozicija, skirta vartoti geriant
GB201212010D0 (en) * 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
PT3479823T (pt) 2015-03-27 2020-09-29 Gruenenthal Gmbh Formulação estável para administração parentérica de tapentadol
EP3120837A1 (de) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Verfahren zur herstellung einer bortezomibester-lösung
WO2017192744A1 (en) * 2016-05-04 2017-11-09 Motif BioSciences Inc. Systems and methods for treating bacterial infection
KR20190057349A (ko) 2016-09-23 2019-05-28 그뤼넨탈 게엠베하 타펜타돌의 비경구 투여용 안정한 제제
CN110818693B (zh) * 2018-08-07 2023-06-02 上海度德医药科技有限公司 一种艾拉普林甲磺酸盐晶型b及其制备方法
WO2020161284A1 (en) 2019-02-07 2020-08-13 Sandoz Ag Crystalline form of iclaprim mesylate
CN110713483B (zh) * 2019-11-18 2023-04-07 上海医药工业研究院 艾拉普林中间体及艾拉普林的制备方法
CN110790753B (zh) * 2019-11-18 2023-04-07 上海医药工业研究院 艾拉普林对甲苯磺酸盐、其制备方法和应用
CN110642792B (zh) * 2019-11-18 2023-04-21 上海医药工业研究院有限公司 艾拉普林中间体的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020839A1 (en) * 1995-12-04 1997-06-12 F. Hoffmann-La Roche Ag Diaminopyrimidines, pharmaceutical compositions containing them and their use as antibacterial
WO2005014586A1 (en) * 2003-08-08 2005-02-17 Arpida Ag Novel process for the preparation of 2h-chromenes
NZ556800A (en) * 2005-02-18 2011-01-28 Acino Pharma Ag Novel processes for the preparation of a 2H-chromene (Iclaprim)

Also Published As

Publication number Publication date
TW200942240A (en) 2009-10-16
MX2010011117A (es) 2011-02-24
CA2721014A1 (en) 2009-10-15
WO2009124586A1 (en) 2009-10-15
ZA201007185B (en) 2013-03-27
KR20110008055A (ko) 2011-01-25
AU2008354622A1 (en) 2009-10-15
EP2280688A1 (de) 2011-02-09
CN102112108A (zh) 2011-06-29
EP2280688B1 (de) 2012-01-25
JP2011516509A (ja) 2011-05-26
BRPI0822580A2 (pt) 2015-06-23

Similar Documents

Publication Publication Date Title
ATE542522T1 (de) Wässrige pharmazeutische formulierung
RU2013123457A (ru) Непрерывное введение l-допа, ингибиторов допа-декарбоксилазы, ингибиторов катехол-о-метилтрансферазы и предназначенные для этого композиции
RU2011153403A (ru) Стабилизированная композиция, содержащая по меньшей мере одно адренергическое соединение
NZ597757A (en) Aqueous insulin preparations containing methionine
PE20110419A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk
RU2011119988A (ru) Композиции инсулинов длительного действия
HRP20221367T1 (hr) Brzodjelujući inzulinski pripravci
EA201200490A1 (ru) Стабильный совместный состав, содержащий хиалуронидазу и иммуноглобулин, и способы его применения
EA201201569A1 (ru) Инъекционная композиция пролонгированного действия для введения антипсихотического препарата
WO2013078257A3 (en) Implantable solid-liquig drug delivery apparatus, formulations, and methods of use
CY1117659T1 (el) Υδατικο διαλυμα που περιλαμβανει 3-κινουκλιδινονες για τη θεραπεια υπερπλαστικης, αυτοανοσης και καρδιακης ασθενειας
UA117480C2 (uk) Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
HUP0202749A2 (hu) Levoszimendánt tartalmazó oldat formájú gyógyszerkészítmény
EA201201617A1 (ru) Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы
EA201591247A1 (ru) Композиции для консервации органов и тканей с увеличенной устойчивостью и сроком хранения
HRP20181079T1 (hr) Sirnk i njena primjena u metodama i kompozicijama za liječenje i/ili prevenciju očnih stanja
WO2008157288A3 (en) A baclofen solution for low-volume therapeutic delivery
PE20090476A1 (es) Soluciones farmaceuticas
CN103637980B (zh) 一种盐酸异丙嗪注射液的制备方法
AR067047A1 (es) Formulaciones acuosas de acetaminofen para inyeccion.
CN103637981B (zh) 一种盐酸异丙嗪注射液
RU2016144342A (ru) Стабильные композиции нейроактивных пептидов
RU2014148062A (ru) Инъекционная фармацевтическая композиция декскетопрофена и трамадола
ES2382513B2 (es) Solución de diálisis que contiene al menos un antagonista de CCR2
UA142976U (uk) Інфузійний розчин